Cheplapharm AG / DE000CHP2222
26.04.2024 - 11:55:19CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth
| Cheplapharm AG / Key word(s): Annual Results/Annual Report 26.04.2024 / 11:55 CET/CEST The issuer is solely responsible for the content of this announcement. CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH Greifswald, 26th April 2024 Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million) EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million) EBITDA margin remains at a high and industry-leading level of 52% (FY2022: 54%) New affiliates in Japan and Switzerland drive transformation into an international group of companies Number of employees grows to 666, an increase of 24% (FY2022: 535) The CHEPLAPHARM Group, a global leader in the acquisition of originator products from the research-based pharmaceutical industry, closed the financial year 2023 with a record revenue of € 1,498.4 million. The company, headquartered in Greifswald/Germany, is continuing its dynamic and profitable double-digit percentage growth track. In addition to the revenue record, the opening of the affiliates in Japan and Switzerland are important milestones in the transformation to an international group of companies. The largest transaction in the company's history, the acquisition of the Zyprexa® portfolio from Eli Lilly for a purchase price of around € 1.3 billion, rounds off the successful financial year 2023. The annual financial statements for the financial year 2023 published today show a year-over-year increase in revenue of +17% to € 1,498.4 million (FY2022: € 1,279.5 million). EBITDA totalled € 780.5 million in the reporting period, an increase of +14% compared to the financial year 2022 (FY2020: € 685.7 million). At 52%, the EBITDA margin remained at a high and industry-leading level in 2023. CHEPLAPHARM is thus continuing its dynamic and profitable growth track over the last years in 2023 as well and significantly exceeding the targets it has set itself. The strong growth in revenue and earnings was driven by the successful acquisitions in 2023, with the largest transaction in the company's history making a particularly significant contribution to growth. In July 2023, CHEPLAPHARM acquired the Zyprexa® portfolio from Eli Lilly for around € 1.3 billion. Further acquisitions of products from Roche (Xeloda® - China and Japan), AstraZeneca (Pulmicort Flexhaler® - USA) and Teva (Myocet® - Europe) also had a positive impact on revenue development and the further diversification of the portfolio. In total, CHEPLAPHARM invested around € 1.8 billion in acquisitions of established branded products in 2023, a record level of investment. "We look back on an extremely successful year 2023 and continued to grow profitably in a challenging market environment. In addition to this dynamic growth, we have also consistently driven forward our transformation into an international group of companies. Within just a few months, we have established two fully operational affiliates in Japan and Switzerland with over 30 new colleagues," says Edeltraud Lafer, CEO of CHEPLAPHARM, summarising the positive results. With the two subsidiaries in two globally important pharmaceutical markets, CHEPLAPHARM is expanding and strengthening its global presence. The new locations will enable economies of scale to be realised and profitability to be further increased. "In the financial year 2023, we were also very successful on the capital market and raised more than one billion euros with two bonds," adds Dr Kia Parssanedjad, CFO of CHEPLAPHARM. "This enabled us to finance the acquisition of the Zyprexa® portfolio and further strengthen our liquidity position. The two successful placements demonstrate investors' great confidence in the strength and resilience of our business model and give us the flexibility to further invest in attractive branded medicines in the current financial year 2024 and thus continue our growth track." As a profitable and steadily growing company, CHEPLAPHARM is an attractive employer. The number of employees rose by 131 to 666 at the end of the year, an increase of 24% compared to the previous year. The majority of the new colleagues started work at the headquarters in Greifswald. This means that CHEPLAPHARM remains one of the most important employers in the region. About CHEPLAPHARM CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 700 people worldwide. Please refer to www.cheplapharm.com for additional information. Press office: CHEPLAPHARM ? Ziegelhof 24 ? 17489 Greifswald ? press(at)cheplapharm.com 26.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Cheplapharm AG |
| Ziegelhof 24 | |
| 17489 Greifswald | |
| Germany | |
| Phone: | 03834 3914 O |
| E-mail: | info@cheplapharm.com |
| Internet: | www.cheplapharm.com |
| ISIN: | DE000CHP2222 |
| WKN: | CHP222 |
| EQS News ID: | 1890701 |
| Notierung vorgesehen |
| End of News | EQS News Service |
| |
